1.Linder JA, et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. American Journal of Medicine 2005; 118: 259–268.
2.Chin NX, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrobial Agents and Chemotherapy 1984; 25: 319–326.
3.Smith JT. Mutational resistance to 4-quinolone antibacterial agents. European Journal of Clinical Microbiology 1984; 3: 347–350.
4.Cullmann W, et al. Comparative evaluation of recently developed quinolone compounds – with a note on the frequency of resistant mutants. Chemotherapy 1985; 31: 19–28.
5.Speciale A, et al. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin. Drugs under Experimental and Clinical Research 1987; 13: 555–561.
6.Goldstein FW, Acar JF. Epidemiology of quinolone resistance: Europe and North and South America. Drugs 1995; 49: 36–42.
7.Hidron AI, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infection Control and Hospital Epidemiology 2008; 29: 996–1011.
8.Bouza E, et al. A European perspective on nosocomial urinary tract infections II. Report on incidence, clinical characteristics and outcome (ESGNI-004 study). European Study Group on Nosocomial Infection. Clinical Microbiology and Infection 2001; 7: 532–542.
9.Naber KG, et al. Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. International Journal of Antimicrobial Agents 2008; 32: 145–153.
10.Smith CE, et al. Assessment of the synergistic interactions of levofloxacin and ampicillin against Enterococcus faecium by the checkerboard agar dilution and time-kill methods. Diagnostic Microbiology and Infectious Diseases 1997; 27: 85–92.
11.Landman D, Mobarakai NK, Quale JM. Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin. Antimicrobial Agents and Chemotherapy 1993; 37: 1904–1908.
12.Whitman MS, et al. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy 1993; 37: 2069–2073.
13.Garner JS, et al. CDC definitions for nosocomial infections, 1988. American Journal of Infection Control 1988; 16: 128–140.
14.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement: M100-S18. Wayne, PA: CLSI, 2008.
15.MacAdam H, et al. Investigating the association between antibiotic use and antibiotic resistance: impact of different methods of categorising prior antibiotic use. International Journal of Antimicrobial Agents 2006; 28: 325–332.
16.Gasink LB, et al. The categorization of prior antibiotic use: impact on the identification of risk factors for drug resistance in case control studies. American Journal of Infection Control 2007; 35: 638–642.
17.Harris AD, et al. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clinical Infectious Diseases 2001; 32: 1055–1061.
18.Lautenbach E, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Archives of Internal Medicine 2002; 162: 2469–2477.
19.Arslan H, et al. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. Journal of Antimicrobial Agents and Chemotherapy 2005; 56: 914–918.
20.Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Annals of Pharmacotherapy 2004; 38: 1148–1152.
21.Rattanaumpawan P, et al. Risk factors for fluoroquinolone resistance in gram-negative bacilli causing healthcare-acquired urinary tract infections. Journal of Hospital Infection (in press).
22.Chen SY, et al. Bacteremia in previously hospitalized patients: prolonged effect from previous hospitalization and risk factors for antimicrobial-resistant bacterial infections. Annals of Emergency Medicine 2008; 51: 639–646.
23.Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infection Control and Hospital Epidemiology 2009; 30: 746–752.
24.Wilson W, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association rheumatic fever, endocarditis, and kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. Circulation 2007; 116: 1736–1754.